On Dec. 12, 2019, Vanderbilt University Medical Center (VUMC) researchers James Crowe Jr., MD, and colleagues announced they had isolated human monoclonal antibodies, isolated from two survivors of H7N9 (bird flu) infections and produced in bulk in the laboratory, that protected mice from an otherwise lethal viral challenge.